comment
| - Emergent BioSolutions ist ein US-amerikanisches Biopharma-Unternehmen. Das Unternehmen entwickelt, produziert und vertreibt unter anderem Pockenimpfstoff (ACAM2000®), Anthraximpfstoff (BioThrax®), Anti-Anthrax-Antikörper (ANTHRASIL®), Heptavalent Botulism Antitoxin (BAT®), Choleraimpfstoff (VAXCHORA®) und Typhusimpfstoff (Vivotif®).
- ( 비슷한 이름의 바이오솔루션에 관해서는 해당 문서를 참조하십시오.) 이머전트 바이오솔루션스(Emergent BioSolutions)는 항체치료제와 백신을 개발하는 미국의 생명공학 기업이다.
- Emergent BioSolutions is een Amerikaanse multinational. De onderneming ontwikkelt preventieve en therapeutische vaccins tegen miltvuur (antrax), botulisme, buiktyfus, hepatitis B en streptococcus (groep B). De multinational, het moederbedrijf van onder meer , is de enige onderneming in de VS die een vaccin tegen miltvuur mag produceren.
- Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson and AstraZeneca/Oxford vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.
|